Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 47Leukemia, Myeloid, Acute 25Recurrence 21Lymphoma, Large B-Cell, Diffuse 13Sarcoma 9Lymphoma 6Neoplasms, Plasma Cell 5Neoplasm Metastasis 5Glioblastoma 5Endometrial Neoplasms 5Ovarian Neoplasms 4Neurofibrosarcoma 4Neoplasms 4Melanoma 4Lymphoma, T-Cell, Peripheral 4Lymphoma, Non-Hodgkin 4Colorectal Neoplasms 4Triple Negative Breast Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Lymphoma, Extranodal NK-T-Cell 3Lymphoma, B-Cell 3Liposarcoma 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Waldenstrom Macroglobulinemia 2Thymoma 2Sarcoma, Alveolar Soft Part 2Rhabdoid Tumor 2

Interventions

tislelizumab 1selinexor 1atezolizumab 1anlotinib 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Cancer × selinexor × Clear all
NCT07172412 2025-09-30

Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
165 enrolled

Extensive Stage Lung Small Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡